CLINICAL AND MOLECULAR HEPATOLOGY

5th Annual International Editorial Board Meeting of CMH. Always a great pleasure to connect with our outstanding editors! We’re continually inspired by the dedication and insights of our international editorial board. We sincerely appreciate the invaluable suggestions that will…

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Long-term kinetics of plasma pgRNA in patients on NUCs Plasma pgRNA declines slower than DNA upon NUC therapy. Only 16% patients achieved RNA undetectability after 5 years NUC indicating cccDNA silencing has not been achieved in the majority of patients. Read more:…

Integrated multiomics study of sarcomatoid HCC This study demonstrated a comprehensive description of the molecular basis for sarcomatoid HCC, and identify genomic alteration (ARID2 mutation) together with the tumor microenvironment (hypoxic microenvironment). Read more:…

Cost-effectiveness and return on investment of HCV elimination in China The strategy with an annual primary screening of 14%, re-screening of the PWID every year and the general population every five years, and treatment of 95% of diagnosed patients was the most cost-effective.…

Prediction of PBC in AMA-M2 Positive Population AMA-M2 could be positive in non-PBC individuals. This study showed that ALP, GGT, IgM, eosinophil (%), gamma globulin (%), HGB, and sex were potential variables for prediction of PBC in this population. Read more:…

Exciting news! "Clinical and Molecular Hepatology" has achieved a 2024 Impact Factor of 16.9, ranking 6th out of 143 in Gastrenterology & Hepatology. Thank you all for your continued support and contributions. Let’s continue this journey together by advancing knowledge and…

TIPS does more than lower portal pressure-it rewires inflammation In decompensated cirrhosis, TIPS leads to a sustained and significant drop in systemic inflammation and bacterial translocation markers (↓25 SIMs, ↓sCD14, ↓CRP), translating into improved outcomes for patients.…

Bariatric surgery improves survival in MASLD and cirrhosis—especially with laparoscopic approach Bariatric Surgery reduced overall mortality by 37% and liver-related mortality by 76% in patients with MASLD and cirrhosis. Especially Laparoscopic surgery showed greater benefit…

A rollover study from the TORCH-B trial: 3-year TDF therapy resulted in favorable histopathological, biochemical, and virological outcomes in CHB patients with minimally raised ALT. 📘 Full article: doi.org/10.3350/cmh.20… #ClinicalLiver #ChronicHepatitisB #CHB #HBV #LiverHealth…

🧪 Aberrant fragmentomic features of ccf-mtDNA for early detection and prognosis prediction of HCC This is the first study to explore the clinical application of ccf-mtDNA fragmentomic features in predicting HCC prognosis, highlighting its potential as a blood-based biomarker…

In this multicenter, retrospective study including CHC patients who were treated with DAAs and achieved a SVR, metabolic dysfunction has an unfavorable influence on fibrosis regression.

📌 Sex-Specific Gut Microbiota Profiles in MASLD: A Clinical Insight 🔍 Could sex differences in gut microbiota explain MASLD heterogeneity? This Clin Mol Hepatol study shows distinct microbial signatures in the jejunum and colon between males and females with MASLD. 🧠 Key…

📢 Universal HCV Self-Testing: A new approach to eliminate HCV! 🩸💡 Our latest study shows that universal HCV self-testing is highly cost-effective and can reduce severe liver disease by 71% while preventing 69% of liver-related deaths. A major step toward the WHO 2030…

📢 USP29 stabilizes ACSL5 to mitigate MASLD Our latest study reveals that USP29 protects against MASLD progression by stabilizing ACSL5 through K48-linked deubiquitination. Enhancing the USP29-ACSL5 pathway could be a novel therapeutic strategy for MASLD management. 🔗 Read…

🔬✨ Phase 2a Clinical Trial on HK-660S for PSC A randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of HK-660S (β-lapachone) in primary sclerosing cholangitis (PSC) patients. Results demonstrated a 15.2% reduction in ALP levels, potential…

🩺 Optimizing CSPH Management: A New Risk Model & Carvedilol Therapy 🩺 A novel risk model based on LSM and PLT enables precise identification of high-risk patients with clinically significant portal hypertension (CSPH). 📊 Carvedilol significantly reduces the risk of hepatic…

In this episode, Soon Kyu Lee and colleagues identify the optimal tacrolimus level for reducing the risk of chronic kidney disease (CKD). They also examine the impact of intrapatient variability in tacrolimus levels on CKD development, emphasizing the importance of meticulous…